

# Special Issue

## Research on Pharmacotherapy of Metabolic-Associated Fatty Liver Disease

### Message from the Guest Editor

This special issue will delve into liver diseases, specifically focusing on the pharmacotherapy of Metabolic-Associated Fatty Liver Disease (MAFLD). Encompassing viral infections and metabolic disorders falling (after nomenclature change in June 2023 during EASL conference) under the umbrella term SLD (Steatotic Liver Disease), including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Alcohol-Related Liver Disease or Drug-Induced Liver Injury (DILI), it highlights the crucial role of metabolomics in understanding liver conditions. Authors are encouraged to investigate disruptions in both endogenous and exogenous metabolites, utilizing advanced techniques like lipidomics, cheminformatics, and computational chemistry. The issue underscores the significance of metabolomics in offering insights for early diagnosis, steering targeted therapies, and cultivating a profound understanding of metabolic dysregulation in hepatic disorders. Dr. Bołdys

---

### Guest Editor


Dr. Aleksandra Bołdys

Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medykon 18, 40-752 Katowice, Poland

---

### Deadline for manuscript submissions

closed (1 April 2025)



# Metabolites

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.7

CiteScore 6.9

Indexed in PubMed



[mdpi.com/si/194296](https://mdpi.com/si/194296)

*Metabolites*

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland


Tel: +41 61 683 77 34

[metabolites@mdpi.com](mailto:metabolites@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/metabolites)

[metabolites](https://mdpi.com/journal/metabolites)





# Metabolites

an Open Access Journal  
by MDPI

Impact Factor 3.7  
CiteScore 6.9  
Indexed in PubMed



[mdpi.com/journal/  
metabolites](http://mdpi.com/journal/metabolites)

## About the Journal

### Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

---

### Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).

